Abstract
Virotherapy in one of the main current applications of recombinant adenoviruses. Oncolytic adenovirus are designed to target tumors, replicate selectively in tumor cells, and elicit immune responses against tumor antigens. Transgene expression in replication-competent oncolytic vectors allows to explore multiple strategies to enhance the potential of virotherapy. In this chapter we describe common in vivo and in vitro techniques used to evaluate the potency and biodistribution of oncolytic viruses. Monitoring immune responses against viral and tumor antigens is crucial as the immune system determines the outcome of virotherapy.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Choi JW, Lee JS, Kim SW, Yun CO (2012) Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 64(8): 720–729
Pesonen S, Kangasniemi L, Hemminki A (2011) Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 8:12–28
Wang Y, Hallden G, Hill R, Anand A, Liu TC, Francis J et al (2003) E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol 21:1328–1335
Funston GM, Kallioinen SE, de Felipe P, Ryan MD, Iggo RD (2008) Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping. J Gen Virol 89:389–396
Guedan S, Grases D, Rojas JJ, Gros A, Vilardell F, Vile R et al (2012) GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Ther 19:1048–1057
Guedan S, Rojas JJ, Gros A, Mercade E, Cascallo M, Alemany R (2010) Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Mol Ther 18:1275–1283
Kast WM, Melief CJ (1991) Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumours and peptide-MHC binding. Int J Cancer Suppl 6:90–94
Toes RE, Offringa R, Blom RJ, Brandt RM, van der Eb AJ, Melief CJ et al (1995) An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J Immunol 154:3396–3405
Acknowledgments
This work was supported by a grant from the Spanish Ministry of Education and Science BIO2011-30299-C02-01, BIO2008-04692-C03-01 and from the Generalitat de Catalunya 2009SGR1212.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Gil-Hoyos, R., Miguel-Camacho, J., Alemany, R. (2014). Oncolytic Adenovirus Characterization: Activity and Immune Responses. In: Chillón, M., Bosch, A. (eds) Adenovirus. Methods in Molecular Biology, vol 1089. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-679-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-62703-679-5_9
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-678-8
Online ISBN: 978-1-62703-679-5
eBook Packages: Springer Protocols